Eckert & Ziegler's isotope treat first brain cancer case
Isotope provider Eckert & Ziegler have utilized its brachytherapy product, IsoSeed for the treatment of a brain tumor patient from Helsinki University Central Hospital in Finland.
According to the Berlin-based company, the radioactive, miniaturized seeds used for brachytherapy previously have been used for the treatment of early-stage prostate cancer, and were administered to the patient by way of Eckert & Ziegler’s radiation technology Belgian subsidiary, IBt Bebig.
According to the Berlin-based company, the radioactive, miniaturized seeds used for brachytherapy previously have been used for the treatment of early-stage prostate cancer, and were administered to the patient by way of Eckert & Ziegler’s radiation technology Belgian subsidiary, IBt Bebig.